Introduction
Between 5% and 70% of the patients with pulmonary carcinoids will develop metastases [1] [2] [3] [4] , most often to regional lymph nodes but also distantly to the liver, bones, brain, subcutaneous tissue, or mammary glands. Metastases may occur late, years or decades after the initial diagnosis. The overall five-year survival rate is 87%-93% and the 10-year survival rate is 77%-87% [5] [6] [7] . The only curative treatment is surgery in order to remove the primary tumor and affected lymph nodes. Radiotherapy is primarily used as palliative treatment of local or bone metastases but may also be considered for the primary tumor area if radical surgery is not possible. Various regimens of chemotherapy have been tried, including combinations of cisplatinum + etoposide or streptozotocin + 5-fluorouracil (5-FU). Alphainterferon has also been used on these patients. For symptomatic relief of disabling carcinoid syndrome, octreotide is useful, alone or in combination with ainterferon.
The indications for and effect of the various treatment regimens have so far not been sufficiently evaluated. Our first-line treatment in patients with metastatic pulmonary carcinoids has been oe-interferon. In case of disabling carcinoid syndrome, oc-interferon has been combined with octreotide. When this therapeutic regimen has failed, we have switched to streptozotocin + 5-fluorouracil (5-FU). Patients that showed progressive disease while using the latter combination have been converted to cisplatinum + etoposide as a third line therapy. Liver embolization with gel-foam has been used as second or third line treatment when the vast majority of the tumor burden was located in the liver. Our intention has been to monitor the patients every third month by means of CT scans or ultrasonography, and measurement of circulating tumor marker levels. In this paper, we report our experience of treating 31 patients with pulmonary carcinoid tumors, all harboring metastatic disease. We also describe the usefulness of measurements of various secreted peptides and amines as markers for diagnosis.
Patients and methods

Patients
The patient characteristics are summarized in Table I All patients with metastatic pulmonary carcinoids (n = 31; 14 men and 17 women) treated at the Department of Endocrine Oncology. University hospital. Uppsala were included in this study. Their median age was 60 years (range . Four patients had atypical carcinoids. while 27 patients had typical carcmoids according to the recent WHO classification [8, 9] , The primary tumor was centrally located in 19 patients and peripheral in six patients: in the remaining six patients, the position of the primary tumor was not known. Surgery of the primary tumor had been performed in 22 patients according to the following' local excision in three (two of these were later subjected to repeated surgery with lobectomy and pneumonectomy. respectively), lobectomy in nine, bilobeetomy in live (one of these was operated on during the study) and pneumonectomy in five cases In addition, seven patients were operated on for distant metastases (brain, skin, mammary gland and ovaries two patients each, pituitary one patient) and one patient was subjected to repeated laser surgery for intrabronchial recurrences. Radiotherapy against the primary tumor or intrathoracic recurrence was given to seven patients, while seven received palliative radiotherapy for bone metastases. two for brain nietastases and one patient for a pituitary metastasis All patients had distant metastases and were in stage IV at the start of treatment except two patients (nos. 12 and 28) who were classified as stage Ilia because lymph node metastases were found at surgery of the primary tumor. Patient 12 was later reclassified as stage IV because of development of distant metastases and patient 28 was reclassified as stage 1Mb because of extensive intrathoracic tumor growth Metastases most frequently occurred to the liver (25 patients), bones (18 patients) and lymph nodes (12 patients), while four tumors metaslasized to the brain and three to the mammary glands (Table 1) : all except one patient (no 28) had extrathoracic involvement. Carcinoid syndrome was observed in 16 patients (all harboring liver metastases), while two had ectopic Cushing's syndrome due to production of ACTH. Median follow-up time from treatment start was 25 months (range 4-106).
Hormones
Plasma chromogranin A, chromogranin B, serum pancreatic polypeptide (PP), serum calcitonin and serum human chorionic gonadotrophin subunits a and p (hCGoc and hCGp) were repeatedly analysed according to methods described earlier [10] [11] [12] [13] [14] . Urinary excretion of 5-hydroxy-indole-acetic acid (5'H1AA) was measured on two consecutive days and the mean value was calculated. Twenty-four hour urinary excretion of tele-methylimidazoleacetic acid (MelmAA). the principal metabolite of histamine. was measured as described earlier [15] .
Treatment schedules
The various used treatments given to the individual patients is shown in Table 2 . a-lnterferon has been used in 28 patients and y-interferon in 14. The dose of ot-interferon has varied between 9-42 (median 15) 5   6  7  8a  9  10  II  12a  13  14  15  16  17   18   19a   20  21  22   23   24  25  26  27  28  29  30 Stage   IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  llla-IV  IV  IV  IV  IV  IV  IV   IV   IV  IV  IV  IV  IV  IV  IV  IV llla-lllb IV IV IV Position (primary tumor) million units/week divided into 3 or 5 subcutaneous injections, and side effects and compliance have been taken into consideration when deciding on dose alterations. Somatostatin analogues have been administered to 18 patients (lanreotide in one case and octreotide in all 18), alone or in combination with interferon or chemotherapy. Altogether 18 patients have received chemotherapy. The following regimens have been used (Table 3) : Cisplatinum + etoposide (/; = 8), streptozotocin + 5-FU (n = 7). streptozotocin + doxorubicin (it = 2). a-interferon + 5-FU (it = 2), paclitaxel (n = 2) and paclitaxel + doxorubicin (n = 2). Liver embohzation with gel-foam was performed in altogether five patients, on one occasion in one patient, on two occasions in two and on three occasions in two patients. Targeted radiotherapy was administered to three patients, two of whom received "'In-Octreotide and one'"l-MIBG When evaluating the treatment outcomes, a >50% decrease of at least one hormone marker was considered a biochemical response, while a ^ 25% increase of at least one hormone marker was considered biochemical progression Similarly, a > 50% decrease in tumor size (product of two perpendicular measures on CT scan) was considered an objective response and a >25% increase in tumor size or the occurrence of new metastases was considered progression. Time to progression was defined as the time from treatment start to the first occcasion when progression was observed. Duration of response was defined as time from treatment start to the last occasion when disease was considered stable. 
Immunohistochemistry
Analysis of the imniunohistocheniical profile of the tumor was performed wherever paraffin blocks could be collected (n = 18). according to methods described earlier The following antibodies were used: Ki-67. CD44. hCGa. GRP. serotonin, bcl-2. nm23 and p53 [16] . 
Statistics
Intergroup comparisons were made by the Mann-Whitney U-test. Correlations were analyzed by the chi-square test. P < 0.05 was considered significant. The Kaplan-Meier product limit method was used for survival analysis.
Results
Tumor markers
The results from measurements of hormone levels are shown in Table 4 . Chromogranin A and B were the most frequently elevated hormones, 93% and 86% respectively. The levels of chromogranin A (times upper reference limit) were significantly higher than the chromogranin B levels (P < 0.01). Sixty-eight percent (21 patients) had increased U-5'HIAA. Patients with liver metastases had higher chromogranin A levels than patients without liver metastases (P < 0.01). A carcinoid syndrome was present in 16 of the 21 patients with elevated U-5'HIAA. The 16 patients displaying carcinoid syndrome had significantly higher U-5'HIAA levels than those five patients with elevation of U-5'HIAA but without the carcinoid syndrome (P < 0.01).
Biotherapy
Results of biotherapy in individual patients are shown in Table 5 . Twenty-seven patients were treated with ainterferon, alone or in combination with octreotide and/ or y-interferon. Symptomatic relief of the carcinoid syndrome was obtained in 7 of 16 patients. Two patients had no detectable tumor disease and normal hormone levels at the start of adjuvant a-interferon treatment. They both developed metastases after 23 and 33 months respectively. In 21 of 27 patients (10 receiving only ainterferon, 10 treated with a-interferon + octreotide and one given a-interferon + y-interferon), the tumor disease progressed radiologically (/; = 17), biochemically (n = 8) the carcinoid syndrome, and no correlation could be detected between response to treatment and the results of any of the immunohistochemical analyses. There was no difference in objective response or survival between those patients treated with the combination of a-interferon + octreotide compared to a-interferon as single drug, neither did treatment response correlate to K.i-67 expression or any of the other tumor products analysed by immunohistochemistry. The combination of a-interferon and y-interferon was used in nine patients (of whom one had it as first line treatment). Three of these patients stopped y-interferon after less than two months due to side effects. One patient, who had progressed on single treatment with a-interferon, was biochemically stable for 18 months and showed stable radiology lasting 11 months following inclusion of y-interferon to the regimen. The other five patients progressed after 1-4 months. y-Interferon was given as a single drug to three patients. In all three cases, y-interferon was withdrawn within 1-6 months due to intolerable side effects (pt. no. 20) or progressive disease (pt. nos. 10 and 29). Two patients (nos. 9 and 23) received y-interferon in combination with octreotide. Both were stable for 10 and 29 months, respectively. Progression was later recorded even in these cases.
Somatostatin analogues were given as single drugs in four cases resulting in progressive disease in all of them. One experienced disabling side effects, another patient benefited from relief of a carcinoid syndrome, but the remaining two had insufficient or short-lasting effects on their carcinoid syndrome.
Abbreviations: IFN -interferon; SMS -octreotide: Lan -lanreotide: NE -not evaluated; D -treatment discontinued because of insufficient clinical effect " SMS was added after 15 months b Octreotide was added after one year. Patients 1,6. 11 and 20 stopped y-interferon after less than two months because of side effecs.
and/or displayed intractable endocrine symptoms (n = 2). Four (4 of 27) patients, all harboring typical carcinoids, (three treated with a-interferon + octreotide and one with a-interferon as a single drug) showed stable disease for 15 months (median). There was no difference in the frequency of response among patients with or without Eight patients received 3-8 courses (median 6) of cisplatinum + etoposide. One patient was concomitantly given a-interferon (no. 14). The results are shown in Table 6 . Two patients (both harboring typical carcinoids) had an objective response for six and eight months respectively, and one (with an atypical carcinoid) had stabilization of disease for seven months. The tumors in the remaining five patients (four typical carcinoids and one atypical) continued to grow after 3-4 months, although the hormones decreased and symptomatic relief was obtained in the patient who was treated with concomitant a-interferon. Patients with the carcinoid syndrome responded less frequently to cisplatinum + etoposide than patients without this syndrome (P -0.03). There was no correlation between response to treatment and Ki-67 expression or any of the other tumor products analysed by immunohistochemistry.
Seven patients were given 5-15 courses (median eigth) of streptozotocin + 5-FU; two received concomitant ainterferon (Table 7) . One patient showed stable disease for eight months and progressive disease after 12 months. The tumors of the other six patients were obviously resistant to streptozotocin + 5-FU and showed progression. Both patients treated with a combination of a-interferon and streptozotocin + 5-FU progressed. Streptozotocin + doxorubicin was given to two patients (II and 12 courses respectively). Both patients (nos. 14 and 31, Table 2 ) displayed radiologically stable disease for 8 and 10 months, respectively. One of the patients showed decrease of hormone markers and the other one had biochemically stable disease.
The combination of paclitaxel + doxorubicin was used in two cases. One patient (no. 8) who received eight courses, was stable for nine months while the other (no. 18), being treated with 10 courses, had stable disease in the liver for 11 months although her bone metastases progressed after nine months.
Two patients were treated with paclitaxel as a single drug. One of them received three courses but showed progressive disease after one month. The other patient, who was subjected to eight courses altogether, displayed radiologically stable tumor size but progressed biochemically after seven months.
The two patients that were given 5-FU in combination with a-interferon both showed progressive disease after three and six months, respectively.
Targeted radiotherapy
Targeted radiotherapy was given as third or fourth line therapy in three patients. Two of these patients received '"in-Octreotide and one was subjected to I3I I-MIBG.
All three showed progressive disease at the first followup after 3-6 months.
Liver emboHzation
Five patients underwent liver embolization with gelfoam. The procedure was performed on one occasion in one patient, on two occasions in two patients and on three occasions in two patients. The patient that only had one embolization performed (no. 12) reported a temporary clinical improvement and the procedure resulted in biochemically stable disease for four months. Although the liver metastases decreased < 50%, the disease progressed in other organs. After eight months, the liver metastases also started to grow and the hormone levels increased. One patient underwent embolization of both liver lobes with a two month interval (pt. no. 18). She was biochemically and radiologically stable until progression was noted 12 months from the first treatment. Another patient (no. 22) was embolized twice in the right liver lobe at four months' interval. Clinical improvement and biochemical and radiological regression were noted after the first procedure. Progressive disease was however noted 23 months after the first event. One patient underwent three embolizations of the right lobe at 1 and 1.5 years' interval, respectively (no. 31). Clinical improvement of disabling carcinoid syndrome was observed after all three treatments. After the first embolization, she was radiologically stable for 11 months and the hormones decreased significantly. After the following two embolizations, she was biochemically stable but progressed radiologically. The last patient (no. II) was first embolized in both lobes at two month intervals and after one year again in the right lobe. His hormones decreased after the first treatment and he was radiologically stable nine months after the first and 11 months after the third embolization.
Prognosis
Median survival from the initial diagnosis was 76 months . Five-year survival from treatment start was 22% (Figure la) , while 5-and 10-year survival from the initial diagnosis was 70% and 54%, respectively (Figure lb) . Twenty-four patients have died after median 26 months (4-106), and seven patients are alive with disease after median 23 months (18-71).
Discussion
Plasma chromogranin A, which is recognized as a valuable tumor marker both in midgut carcinoids [17] and gastric carcinoids [18] , appears to be the most sensitive marker in metastatic pulmonary carcinoids as well. Patients with liver metastases had higher chromogranin A levels than patients without liver metastases, which may imply a correlation between plasma chromogranin A level and tumor burden. The low specificity of a marginally increased chromogranin A level [19] makes it unreliable for differential diagnosis of a lung tumor found on chest X-ray. Only one patient with chromogranin A within the reference range had elevation of chromogranin B. The efficacy of chromogranin B as a marker for bronchial carcinoids has not been investigated, and the present data implies that a study designed for such an evaluation is warranted. In our material of metastatic typical and atypical pulmonary carcinoids, the carcinoid syndrome occurred in half the patients. About two thirds had elevation of urinary 5'HIAA which may be used as a tumor marker in patients with metastatic pulmonary carcinoids. The elevation was however less prominent in the absence of carcinoid syndrome. None of the patients without Cushing's syndrome had elevation of plasma ACTH or urinary cortisol. In the absence of clinical symptoms, it does not seem useful to measure these two hormones.
For patients with malignant midgut carcinoids biotherapy with a-inlerferon and somatostatin analogues improves prognosis [20] and offers good symptomatic relief. In pulmonary carcinoid patients however, the effect of oc-interferon and octreotide on tumor growth seems to be more limited; only a few patients showed stable tumor size. The benefit of adding y-interferon to the oc-interferon regimen is not very obvious in this patient material. Our study indicates that a substantial proportion of patients with pulmonary carcinoids suffering from the classical carcinoid syndrome are symptomatically relieved by oc-interferon and octreotide.
Chemotherapy with streptozotocin and 5-FU has produced promising results in patients with endocrine pancreatic tumors [21] , but the effect on pulmonary carcinoids is disappointing. On the other hand, consistent with earlier data in endocrine pancreatic tumors [22] , some patients with pulmonary carcinoids may respond to streptozotocin and doxorubicin. The efficacy of treatment with the combination of doxorubicin and streptozotocin in patients with pulmonary carcinoids needs to be evaluated in a controlled study.
The rapidly growing SCLC are highly responsive to chemotherapy with cisplatinum and etoposide, although the response is usually short-lived. We have noted an objective response or stable disease in 3 of 8 patients with bronchial carcinoids. The patients showing significant reduction of tumor size had typical carcinoids with 1% and 3% Ki-67-positive cells, respectively. This is somewhat surprising considering the results of cisplatinum + etopside in treatment of endocrine pancreatic tumors, where functioning, highly differentiated tumors did not respond. On the other hand, non-functioning, anaplastic tumors of the endocrine pancreas showed objective reduction in 67% of the patients [23] . Although none of the patients experienced complete remission and renal or neurologic side-effects limit the number of tolerated courses, this is still encouraging and should be further studied. Notably, all three patients responding to cisplatinum and etoposide with decrease or stable disease receceived this combination as first-line treatment for their carcinoids. On the contrary, only one of the five patients showing progressive disease received cisplatinum + etoposide as first-line therapy. If this means that cisplatinum combined with etoposide may be used as adjunctive treatment in cases when lymph node metastases are found at surgery of the primary tumor, the treatment still needs to be further studied in a randomized, controlled, multi-center trial, which will however have to wait until the anti-tumoral effect of the combination on pulmonary carcinoids has been confirmed.
The role of targeted radiotherapy in pulmonary carcinoids is still being investigated. None of our three patients treated with radiolabelled octreotide or MIBG benefitted from the therapy, but the limited number of patients and the fact that all three were suffering from advanced disease warrants caution when interpreting the data.
As could be expected from earlier data regarding midgut carcinoids [24] , liver embolization may be of value for debulking of liver metastases even in patients with pulmonary carcinoids. We observed stable disease lasting more than one year, a decrease in tumor marker levels and symptomatic relief. The duration of the effect was however limited and most pronounced after the first embolization in each lobe.
The prognosis in our material of metastatic pulmonary carcinoids was poor. Although the five-year survival from initial diagnosis was 70%, five-year survival from treatment start was only 22%. This is due to the fact that these tumors may develop metastases late, after many years. Patients were usually not referred to us for medical treatment until distant metastases were recognized. It was not always possible to accurately determine how many of our patients had lymph metastases at primary surgery due to variable quality of the recording of the operative procedure. Since the risk to develop distant metastases is greater if lymph node metastases are present at diagnosis [5, 16, 25] , a thorough dissection of peribronchial and hilar lymph nodes using frozen sections is mandatory during surgery for primary pulmonary carcinoids.
In conclusion, radical surgery still offers the only possibility to cure patients with pulmonary carcinoids. Although a few patients can survive for several years despite distant metastases, the treatment of patients with widespread disease is dismal. Liver embolization offers symptomatic relief and temporary stabilization. Individuals suffering from endocrine symptoms may benefit from the combination of a-interferon and octreotide. Chemotherapy, either with cisplatinum + etoposide or combinations containing doxorubicin may produce objective responses or stabilization of the disease for limited periods of time.
